Showing 1691-1700 of 2054 results for "".
- Eyepromise Introduces Screen Shield Teen All-Natural Eye Vitamin for Screen Time Protectionhttps://modernod.com/news/eyepromise-introduces-screen-shield-teen-all-natural-eye-vitamin-for-screen-time-protection/2476410/EyePromise announced the introduction of Screen Shield Teen to its premium EyePromise eye vitamin line. Screen Shield Teen is an ocular nutrition supplement specially formulated to preserve and support visual comfort and wellness for children ages 4-17. The vast majority of teens in the Un
- Roche/Genentech Study Shows First-Time Proof That AI Can Detect Severity of DMEhttps://modernod.com/news/roche-genentech-study-shows-first-time-proof-that-ai-can-detect-severity-of-dme/2476347/A new study published in the journal
- Bascom Palmer Eye Institute Ranked Nation’s No. 1 in Ophthalmology for 17th Timehttps://modernod.com/news/bascom-palmer-eye-institute-ranked-nations-no-1-in-ophthalmology-for-17th-time/2479945/U.S News & World Report has once again ranked Bascom Palmer Eye Institute of the University of Miami Health System as the nation’s best in ophthalmology. Recognized as a global leader in vision research, medical education and patient care, Basco
- New Study Suggests Indoor Visual Habits May Be Driving Myopia Surgehttps://modernod.com/news/new-study-suggests-indoor-visual-habits-may-be-driving-myopia-surge/2485803/For years, the global rise in myopia has largely been blamed on increased screen time, particularly among children and young adults. But new research from scientists at the SUNY College of Optometry suggests the explanation may be more nuanced—and rooted in a common
- Regenxbio Completes Enrollment in ATMOSPHERE and ASCENT Trials of Sura-Vec Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-gene-therapy-for-wet-amd/2484155/Regenxbio announced the completion of enrollment in its two pivotal phase 3 studies—ATMOSPHERE and ASCENT—evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet age-related macular degeneration (
- SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectivenesshttps://modernod.com/news/sightglass-vision-new-18-month-data-reinforce-dot-lens-effectiveness/2484152/New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times th
- FDA Grants Fast Track Designation to Sanofi’s Investigational Gene Therapy for Wet AMDhttps://modernod.com/news/fda-grants-fast-track-designation-to-sanofis-investigational-gene-therapy-for-wet-amd/2484142/The FDA has granted fast track designation to Sanofi's SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA&rs
- NICE Approves First NHS Treatment for Leber Hereditary Optic Neuropathy (LHON)https://modernod.com/news/nice-approves-first-nhs-treatment-for-leber-hereditary-optic-neuropathy-lhon/2484140/The UK-based National Institute for Health and Care Excellence (NICE) has approved idebenone (Raxone; Chiesi Pharmaceuticals) for the treatment of Leber Hereditary Optic Neuropathy (LHON) in patients aged 12 years and older. This marks the first time NICE has
- Orbis Flying Eye Hospital Begins 2-Week Training Project to Improve Eye Care Across Rwandahttps://modernod.com/news/orbis-flying-eye-hospital-begins-two-week-training-project-to-improve-eye-care-across-rwanda/2482898/The Orbis Flying Eye Hospital landed in Kigali, Rwanda, on July 18, 2025, marking the beginning of a historic 2-week training project. It marks the first time this aircraft has visited Rwanda, where Orbis' teams of clinical staff and volunteer faculty will work alongside t
- Sanofi’s Intravitreal Gene Therapy Earns FDA Fast Track Designation for Geographic Atrophyhttps://modernod.com/news/sanofis-intravitreal-gene-therapy-earns-fda-fast-track-designation-for-geographic-atrophy/2482888/The FDA has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The fast track designation process aims to facilitate the developm